We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$632M
AUM Growth
-$12.8M
Cap. Flow
-$44.8M
Cap. Flow %
-7.08%
Top 10 Hldgs %
85.21%
Holding
32
New
4
Increased
11
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$25.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$15.9M
3
CYTK icon
Cytokinetics
CYTK
+$7.39M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$6.41M
5
ACHV icon
Achieve Life Sciences
ACHV
+$4.82M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$13.2M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$10M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$4.05M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$1.43M
5
PTN
Palatin Technologies
PTN
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 76.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$614M
$141M 22.33%
10,995,437
-112,349
-1% -$1.22M
LGND icon
2
Ligand Pharmaceuticals
LGND
$5.94B
$118M 18.65%
3,034,676
-325,879
-10% -$13.2M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$67.1M 10.61%
14,715,786
+6,228,859
+73% +$25.8M
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
$47.9M 7.57%
8,181,816
+385,300
+5% +$2.16M
RCPT
5
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$38.8M 6.13%
910,600
+459,800
+102% +$15.9M
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
$31.9M 5.05%
1,643,046
+142,750
+10% +$2.52M
GYRE icon
7
Gyre Therapeutics
GYRE
$648M
$30M 4.75%
8,451
+614
+8% +$2M
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$19.5M 3.08%
1,253,000
+117,000
+10% +$1.68M
OMED
9
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$19.2M 3.04%
825,647
-164,131
-17% -$4.05M
TBRA
10
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$17.7M 2.8%
289,677
+105,334
+57% +$6.41M
QLTI
11
DELISTED
QLT Inc
QLTI
$14.6M 2.32%
2,370,263
– –
TRVN
12
DELISTED
Trevena, Inc.
TRVN
$6.32M 1%
1,790
+1,230
+220% +$3.84M
CYTK icon
13
Cytokinetics
CYTK
$10.9B
$6.29M 1%
1,317,000
+1,211,295
+1,146% +$7.39M
ARQL
14
DELISTED
Arqule Inc
ARQL
$4.84M 0.77%
3,124,887
+675,500
+28% +$1.06M
EXEL icon
15
Exelixis
EXEL
$14.1B
$3.39M 0.54%
+1,000,000
New +$3.45M
ACHV icon
16
Achieve Life Sciences
ACHV
$647M
$3.22M 0.51%
+392
New +$4.82M
BLRX
17
BioLineRX
BLRX
$11.7M
$3.12M 0.49%
2,502
+1,169
+88% +$1.46M
KBIO
18
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$2.65M 0.42%
+145,250
New +$2.49M
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.9M 0.3%
69,953
– –
AKAO
20
DELISTED
Achaogen Inc
AKAO
$1.75M 0.28%
125,000
– –
QURE icon
21
uniQure
QURE
$2.93B
$1.7M 0.27%
+125,000
New +$1.36M
PTN
22
Palatin Technologies
PTN
$13.9M
$1.59M 0.25%
1,289
-959
-43% -$1.37M
BIND
23
DELISTED
BIND THERAPEUTICS INC
BIND
$1.53M 0.24%
116,000
– –
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$1.49M 0.24%
1,542
– –
SPHS
25
DELISTED
Sophiris Bio, Inc.
SPHS
$1.34M 0.21%
600,000
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2014 Portfolio in Review

As of Q2 2014, BVF Inc held 32 positions worth $632M, down 2% from $645M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

BVF Inc withdrew a net $44.8M in Q2 2014, closing 3 positions and reducing 4 holdings. Its most notable exit was Rigel Pharmaceuticals, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 72% a quarter earlier.

Against the trend, BVF Inc opened a new position in Achieve Life Sciences worth $3.22M.

  • BVF Inc's largest Q2 2014 buy was Achieve Life Sciences: 392 shares worth $3.22M.
  • BVF Inc added most to Array Biopharma Inc in Q2 2014, an estimated $25.8M increase.
  • BVF Inc's biggest Q2 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $13.2M.
  • BVF Inc fully exited Rigel Pharmaceuticals in Q2 2014, selling an estimated $10M.
  • BVF Inc's ten largest holdings make up 85% of its $632M portfolio in Q2 2014.
  • BVF Inc opened 4 new positions and closed 3 in Q2 2014.
  • BVF Inc's portfolio value fell 2% quarter-over-quarter to $632M.

Based on BVF Inc's 13F filing for Q2 2014, filed 14 Aug 2014.